Alliance Global Partners lowered the firm’s price target on Assertio (ASRT) to $1.50 from $1.75 and keeps a Buy rating on the shares following the Q1 report. The company’s Q1 revenue was below forecast driven largely by Rolvedon, the analyst tells investors in a research note. Now that Assertio appears to have cleaned up the opioid overhang litigation, the share price should start tracking Rolvedon, for better or worse, contends Alliance Global .
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASRT:
- Assertio Therapeutics Reports Q1 2025 Financial Results
- Is ASRT a Buy, Before Earnings?
- Assertio Therapeutics: Balancing Short-term Challenges with Long-term Optimism and Strategic Growth Initiatives
- Assertio Holdings price target lowered to $3.50 from $4 at H.C. Wainwright
- Assertio Therapeutics: Strategic Growth and Financial Resilience Amidst Market Volatility